EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Treatment-related hearing loss in weekly versus triweekly cisplatin chemoradiation for head and neck cancer

A V M Burger, C W Duinkerken, K E van Sluis, J P de Boer, A Navran, C P Lanting, K Jóźwiak, W A Dreschler, A J M Balm, C L Zuur

European Archives of Oto-Rhino-Laryngology · 2024-12 · 281 (12) · 6627-6635

DOI: 10.1007/s00405-024-08880-x ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Archives of Oto-Rhino-Laryngology, online erschienen am 06.09.2024. Verfasst von A V M Burger und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek, Plesmanlaan 121, Amsterdam, 1066 CX, The N…. Hauptthemen laut MEDLINE: Cisplatin, Chemoradiotherapy, Head and Neck Neoplasms, Audiometry, Pure-Tone. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Cisplatin-induced hearing loss is a common side effect in patients treated with cisplatin-based chemoradiation (CRT) for head and neck squamous cell carcinoma. The extent of hearing loss after concurrent CRT was compared between triweekly (3 × 100 mg/m 2 ) and weekly (7 × 40 mg/m 2 ) cisplatin CRT.

Method

This retrospective cohort study was conducted in the Antoni van Leeuwenhoek Hospital and included 129 patients with cisplatin-based CRT for head and neck cancer (72 treated in the triweekly and 57 in the weekly regimen). Baseline and follow-up pure tone audiometry was conducted to assess hearing loss. Clinically relevant hearing loss was defined as a decline upon treatment of ≥ 10 decibel at a pure tone average 1-2-4 kHz and/or 8-10-12.5 kHz.

Results

The incidence of clinically relevant cisplatin CRT induced hearing loss was 42% in the triweekly versus 19% in the weekly group ( p < 0.01). The mean threshold shift at a pure tone average (PTA) 1-2-4 kHz was 9.0 decibel in the triweekly compared to 4.3 decibel in the weekly CRT group ( p < 0.01). At PTA 8-10-12.5 kHz, the incidence of clinically relevant hearing loss was 75% in the triweekly compared to 74% in the weekly CRT group ( p = 0.87). The mean threshold shift at PTA 8-10-12.5 kHz was 20.2 decibel versus 15.6 decibel, respectively ( p = 0.07).

Conclusion

Cisplatin-dose reduction to a weekly cisplatin CRT regimen for head and neck cancer may reduce the incidence of clinically relevant hearing loss at frequencies vital for speech perception.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinChemoradiotherapyHead and Neck NeoplasmsAudiometry, Pure-ToneHearing LossAntineoplastic AgentsHumansMaleRetrospective StudiesMiddle AgedFemaleAgedDrug Administration ScheduleAdultCarcinoma, Squamous CellSquamous Cell Carcinoma of Head and Neck

Stichwörter der Autor:innen

ChemoradiotherapyCisplatinHead and neckHearing lossOtotoxicity

Substanzen

CisplatinAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands.
  • Department of Otolaryngology and Head and Neck Surgery, Leiden University Medical Centre, Albinusdreef 2, Leiden, 2333 ZA, The Netherlands.
  • Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Otorhinolaryngology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Institute of Biostatistics and Registry Research, Brandenburg Medical School Theodor Fontane, Neuruppin, Germany.

Zitieren

APA

Burger, A. V. M., Duinkerken, C. W., van Sluis, K. E., de Boer, J. P., Navran, A., Lanting, C. P., Jóźwiak, K., Dreschler, W. A., Balm, A. J. M., & Zuur, C. L. (2024). Treatment-related hearing loss in weekly versus triweekly cisplatin chemoradiation for head and neck cancer. European Archives of Oto-Rhino-Laryngology, 281(12), 6627-6635. https://doi.org/10.1007/s00405-024-08880-x

Vancouver

Burger AVM, Duinkerken CW, van Sluis KE, de Boer JP, Navran A, Lanting CP, et al. Treatment-related hearing loss in weekly versus triweekly cisplatin chemoradiation for head and neck cancer. European Archives of Oto-Rhino-Laryngology. 2024;281(12):6627-6635. doi:10.1007/s00405-024-08880-x

BibTeX
@article{Burger2024,
  author = {Burger, A V M and Duinkerken, C W and van Sluis, K E and de Boer, J P and Navran, A and Lanting, C P and Jóźwiak, K and Dreschler, W A and Balm, A J M and Zuur, C L},
  title = {Treatment-related hearing loss in weekly versus triweekly cisplatin chemoradiation for head and neck cancer},
  journal = {European Archives of Oto-Rhino-Laryngology},
  year = {2024},
  volume = {281},
  number = {12},
  pages = {6627--6635},
  doi = {10.1007/s00405-024-08880-x}
}
Kostenlos starten →